Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

ClinicalTrials.gov ID: NCT03486392

Public ClinicalTrials.gov record NCT03486392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects

Study identification

NCT ID
NCT03486392
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
474 participants

Conditions and interventions

Conditions

Interventions

  • JNJ-64565111 Dose Level 1 Drug
  • JNJ-64565111 Dose Level 2 Drug
  • JNJ-64565111 Dose Level 3 Drug
  • Liraglutide Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 25, 2018
Primary completion
Mar 7, 2019
Completion
Mar 7, 2019
Last update posted
Feb 4, 2020

2018 – 2019

United States locations

U.S. sites
17
U.S. states
15
U.S. cities
17
Facility City State ZIP Site status
Central Phoenix Medical Clinic Phoenix Arizona 85020
Diablo Clinical Research, Inc. Walnut Creek California 94598
Care Partners Clinical Research Jacksonville Florida 32277
Advanced Clinical Research Boise Idaho 83642
Medisphere Medical Research Center, Llc Evansville Indiana 47714
L-Marc Research Center Louisville Kentucky 40213
Milford Emergency Associates, Inc. Marlborough Massachusetts 01752
Central New York Clinical Research Manlius New York 13104
Weill Cornell Medicine New York New York 10065
Rapid Medical Research Cleveland Ohio 44122
Omega Medical Research Warwick Rhode Island 02886
Coastal Carolina Research Center Mt. Pleasant South Carolina 29464
Dallas Diabetes Research Center Dallas Texas 75230
Permian Research Foundation Odessa Texas 79761
Advanced Clinical Research West Jordan Utah 84088
Rainier Clinical Research Center Renton Washington 98057
Allegiance Reserach Specialists, LLC Wauwatosa Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03486392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 4, 2020 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03486392 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →